25.03.2013 - Delays in developing copies of Roche's top-selling biotech drug are justifying the Swiss company's decision to stay out of biotech generics to focus on improved, patented versions...
Advertising Opportunities Print, Digital & Content Solutions
LinkedIn | X (Twitter)